COEP Key Statistics, Chart & Performance
The current stock price of COEP is 15.7 USD. In the past month the price increased by 12.54%. In the past year, price increased by 330.14%.
COEP Latest News, Press Relases and Analysis
COEP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.92 | 399.57B | ||
| AMGN | AMGEN INC | 15.08 | 177.64B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 150.40B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.24 | 115.56B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.96 | 75.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 898.27 | 60.52B | ||
| INSM | INSMED INC | N/A | 43.51B | ||
| NTRA | NATERA INC | N/A | 33.75B | ||
| BIIB | BIOGEN INC | 10.83 | 26.60B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.54 | 21.07B | ||
| INCY | INCYTE CORP | 15.97 | 20.13B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.18B |
Related stock screener links
About COEP
Company Profile
Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company, which engages in developing innovative cell therapy platforms for cancer that can disrupt conventional treatment paradigms and improve patient outcomes. The company is headquartered in Wexford, Pennsylvania and currently employs 5 full-time employees. The company went IPO on 2020-12-17. The firm is focused on developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio is highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. The company is developing a universal, multi-antigen CAR technology licensed by the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and medical researchers at the Karolinska Institute. Its NexGenAI Affiliates Network platform offers AI-powered marketing software and robotic process automation capabilities. The Company’s subsidiaries include Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc. and SNAP Biosciences, Inc.
Company Info
COEPTIS THERAPEUTICS HOLDING
105 Bradford Road, Suite 420
Wexford PENNSYLVANIA US
Employees: 6
Phone: 17249346467
COEPTIS THERAPEUTICS HOLDING / COEP FAQ
What does COEPTIS THERAPEUTICS HOLDING do?
Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company, which engages in developing innovative cell therapy platforms for cancer that can disrupt conventional treatment paradigms and improve patient outcomes. The company is headquartered in Wexford, Pennsylvania and currently employs 5 full-time employees. The company went IPO on 2020-12-17. The firm is focused on developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio is highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. The company is developing a universal, multi-antigen CAR technology licensed by the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and medical researchers at the Karolinska Institute. Its NexGenAI Affiliates Network platform offers AI-powered marketing software and robotic process automation capabilities. The Company’s subsidiaries include Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc. and SNAP Biosciences, Inc.
What is the current price of COEP stock?
The current stock price of COEP is 15.7 USD. The price decreased by -4.38% in the last trading session.
Does COEP stock pay dividends?
COEP does not pay a dividend.
What is the ChartMill technical and fundamental rating of COEP stock?
COEP has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the GICS sector and industry of COEP stock?
COEPTIS THERAPEUTICS HOLDING (COEP) operates in the Health Care sector and the Biotechnology industry.
What is the market capitalization of COEP stock?
COEPTIS THERAPEUTICS HOLDING (COEP) has a market capitalization of 83.84M USD. This makes COEP a Micro Cap stock.
COEP Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to COEP. When comparing the yearly performance of all stocks, COEP is one of the better performing stocks in the market, outperforming 98.87% of all stocks.
COEP Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to COEP. Both the profitability and financial health of COEP have multiple concerns.
COEP Financial Highlights
Over the last trailing twelve months COEP reported a non-GAAP Earnings per Share(EPS) of -17.58. The EPS increased by 63.79% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -260.16% | ||
| ROE | -486.73% | ||
| Debt/Equity | 0.03 |
COEP Forecast & Estimates
For the next year, analysts expect an EPS growth of 98.47% and a revenue growth -100% for COEP